Moxiget400mg Iv 250ml
Moxiget400mg Iv 250ml (Moxifloxacin) IV is a synthetic broad-spectrum antibacterial agent. Chemically, Moxiget 400mg Iv 250ml is a fluoroquinolone and is available as a monohydrochloride salt of 1-cyclopropyl-7-[(S,S)-2,8 diazabicyclo[4.3.0]non-8-yl]-6-flouro-8-methoxy-1,4-dihydro-4-oxo-3 quinoline carboxylic acid. The molecular formula of Moxiget 400mg Iv 250ml is C21H24FN3O4.HCl. Moxiget 400mg Iv 250ml should be used with caution in patients with ongoing proarrhythmic conditions, such as bradycardia or acute myocardial ischemia. Anaphylactic reactions of Moxiget 400mg Iv 250ml in very rare instances can progress to a life threatening shock, in some instances after the first administration. In these cases the treatment with Moxiget 400mg Iv 250ml must be discontinued, medical treatment (e.g. treatment for shock) is required.
As with all quinolones, Moxiget 400mg Iv 250ml should be used with caution in patients with known or suspected CNS disorders or in the presence of other risk factors that may predispose to seizures or lower the threshold. Moxiget 400mg Iv 250ml, in should be used with caution in patients with myasthenia gravis because the symptoms can be exacerbated.
The concomitant administration of an NSAID with a quinolone may increase the risks of CNS stimulation and convulsions .Cisapride, erythromycin, anti-psychotics and tricyclic antidepressants, An additive effect of Moxiget 400mg Iv 250ml and drugs that prolong the QT interval such as cisapride, erythromycin, anti-psychotics and tricyclic antidepressants cannot be excluded; therefore moxifloxacin should be used with caution when given concurrently with these drugs
Moxiget 400mg Iv 250ml is used to treat different types of bacterial infections of the skin, sinuses, lungs, or stomach.
low blood sugar–headache, hunger, sweating, irritability, dizziness, nausea, fast heart rate, or feeling anxious , nerve symptoms in your hands, arms, legs, or feet–numbness, weakness, tingling, burning pain;
When not use
in case of hypersensitivity.